Finding advances search for cure other than liver transplantation
A protein modified to increase the amount of time it circulates in the bloodstream appears to reverse liver fibrosis and cirrhosis in rats, according to results of a study led by Johns Hopkins researchers.
The investigators say the findings, reported ahead of print in the March 3 early view edition of Hepatology, advance the search for a potential cure for the thousands of patients worldwide living with these incurable diseases. At present, there is little effective treatment and no cure other than liver transplantation, which carries its own risks and often fails.
“Our findings demonstrate that the damaging effects of liver cirrhosis in laboratory rats can be effectively treated, and perhaps even reversed, using a protein therapeutic that has been modified to enhance its activity through site-specific conjugation of a polymer that greatly enhances its residence time in the body,” says senior author Justin Hanes, Ph.D., director of the Center for Nanomedicine at the Wilmer Eye Institute at Johns Hopkins. “This approach has tremendous potential to help people with this devastating condition and may also be helpful to the millions of patients with other diseases where fibrosis plays an important role.”
Liver fibrosis and its more severe form, cirrhosis, are caused by scar tissue that forms in the liver that is usually induced by chronic alcohol abuse, infections and autoimmune diseases. The progressive stiffening of the liver, a hallmark of the disorders, occurs when a type of liver cell known as the hepatic stellate cell is “activated” and overproduces the stringy network of proteins called the extracellular matrix that binds cells together.
Being able to turn cirrhosis around, especially in its late stages, would be a great boon, says Seulki Lee, Ph.D., assistant professor in the Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. “That’s because liver fibrosis and cirrhosis can be asymptomatic for decades,” Lee says. “Many patients only seek treatment when their disease becomes very advanced, at which point liver transplant is their only option.”
Lee cautions, however, that his team’s work is years from any possible application to patients.
Scientists have known for more than a decade that a protein called tumor necrosis factor-related apoptosis-inducing ligand — TRAIL, for short — can specifically kill activated hepatic stellate cells that overproduce the extracellular matrix, sparing healthy cells in the liver. However, Lee explains, TRAIL has thus far proven unsuccessful for clinical use because in animal studies, enzymes in the bloodstream quickly degrade it before it has time to work.
Seeking a way to extend TRAIL’s half-life, or the time that it remains intact in the bloodstream, Lee and his colleagues coated TRAIL with polyethylene glycol (PEG), a synthetic polymer that’s widely used as a preservative, lubricant and ingredient in skin creams, and is already being used to extend the bloodstream life of a handful of drugs that treat neutropenia, hemophilia and rheumatoid arthritis.
Lee says initial experiments showed that this “PEGylated” TRAIL had a half-life of between eight and nine hours in monkeys, compared to less than 30 minutes for the unmodified protein. When the scientists intravenously dosed rats that had liver fibrosis with the modified TRAIL for 10 days, the animals’ activated hepatic stellate cells died off. By fighting these bad cells, signs of fibrosis began to diminish. Further investigation showed that multiple genes associated with fibrosis had reduced activity, and the proteins produced by these genes faded away.
Findings were similar in rats with advanced cirrhosis, Lee says. Additionally, when the researchers examined the rodents’ liver tissue under a microscope, they found that animals treated with PEGylated TRAIL had fewer deposits of collagen and other extracellular matrix proteins, offering some evidence that the disease had actually been reversed.
Further experiments showed that PEGylated TRAIL selectively killed human-activated hepatic stellate cells growing in petri dishes while leaving normal liver cells unharmed, suggesting that findings in these animal models could apply to damaged human livers with limited toxicity concerns.
Lee says the research team hopes to develop PEGylated TRAIL for clinical trials in human patients in the next two years. He adds that some preliminary data suggest that the modified protein could also treat other fibrotic diseases as well, such as pancreatic or lung fibrosis, which also have no effective treatment.
“Eventually,” Lee says, “we might be able to develop PEGylated TRAIL into a universal anti-fibrotic agent that can treat many different conditions.”
Learn more: Modified protein reverses cirrhosis in lab rats
The Latest on: Protein therapeutic
[google_news title=”” keyword=”Protein therapeutic” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Protein therapeutic
- ARTHEx Biotech Announces Oral Presentation on ATX-01 at the Oligonucleotide & Peptide Therapeutics (TIDES) Conference 2024on April 19, 2024 at 12:00 am
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming ...
- How a calcium-sensing protein multitaskson April 17, 2024 at 11:31 am
The calcium-sensing receptor is critical for maintaining healthy calcium levels, but CaSR is also well-known for its side hustles. The receptor is increasingly recognized for its ability to detect ...
- Carisma Therapeutics (CARM) Price Target Decreased by 10.00% to 9.18on April 17, 2024 at 9:33 am
The average one-year price target for Carisma Therapeutics (NasdaqGM:CARM) has been revised to 9.18 / share. This is an decrease of 10.00% from the prior estimate of 10.20 dated March 28, 2024. The ...
- Nanoparticle delivery of FZD4 to lung endothelial cells inhibits lung cancer progression and metastaseson April 16, 2024 at 2:28 pm
A recent study from the lab of Tanya Kalin, MD, Ph.D., professor of Child Health and Internal Medicine at the University of Arizona College of Medicine—Phoenix, has shown potential to improve ...
- Larimar Therapeutics gets grant for fusion protein for treating non-nuclear organelle associated disorderson April 15, 2024 at 6:16 am
Discover Larimar Therapeutics' groundbreaking fusion protein patent designed to treat non-nuclear organelle disorders like Friedrich's Ataxia. Learn how this innovative protein is revolutionizing ...
- Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancieson April 15, 2024 at 4:29 am
Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. Read why I'm neutral on NRIX stock.
- Promising Future for Carisma Therapeutics’ Cancer Immunotherapy: A Buy Rating Analysison April 11, 2024 at 5:45 pm
Naureen Quibria, an analyst from Capital One Financial, reiterated the Buy rating on Carisma Therapeutics (CARM – Research Report). The ...
- A promising target for new RNA therapeutics now accessibleon April 10, 2024 at 7:16 am
Only recently, a new era in medicine began with the first RNA vaccines. These active substances are modified RNAs that trigger immune responses of the human immune system. Another approach in RNA ...
- Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6on April 9, 2024 at 4:00 am
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within the ...
via Bing News